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Abstract
Background: Biallelic von Hippel-Lindau (VHL) gene defects, a rate-limiting event in the
carcinogenesis, occur in approximately 75% of sporadic clear-cell Renal Cell Carcinoma (RCC).
We studied the VHL mutation status in a large population-based case group.
Methods: Cases were identified within the Netherlands cohort study on diet and cancer, which
includes 120,852 men and women. After 11.3 years of follow-up, 337 incident cases with
histologically confirmed epithelial cancers were identified. DNA was isolated from paraffin material
collected from 51 pathology laboratories and revised by one pathologist, leaving material from 235
cases. VHL mutational status was assessed by SSCP followed by direct sequencing, after testing
SSCP as a screening tool in a subsample.
Results: The number of mutations was significantly higher for clear-cell RCC compared to other
histological types. We observed 131 mutations in 114 out of 187 patients (61%) with clear-cell
RCC. The majority of mutations were truncating mutations (47%). The mean tumor size was 72.7
mm for mutated tumors compared to 65.3 mm for wildtype tumors (p = 0.06). No statistically
significant differences were observed for nuclear grade, TNM distribution or stage. In other
histological types, we observed 8 mutations in 7 out of 48 patients (15%), 1 mutation in 1 of 6
oncocytoma, 3 mutations in 2 of 7 chromophobe RCC, 2 mutations in 2 of 30 papillary RCC, no
mutations in 1 collecting duct carcinoma and 2 mutations in 2 of 4 unclassified RCC.
Conclusion: VHL mutations were detected in 61% of sporadic clear-cell RCC. VHL mutated and
wildtype clear-cell RCC did not differ with respect to most parameters.
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Historically, the classification of Renal Cell Cancer (RCC)
was based on morphological features. The majority of
RCC are of the clear cell type (~80%); other subtypes are
papillary RCC (10%), chromophobe RRC (5%), collect-
ing-duct carcinoma (1%) and unclassified RCC (3–5%).
Based on the work of numerous investigators, it became
evident that RCC could be divided into genetically distinct
classes: this resulted in the so-called Heidelberg classifica-
tion, which partly overlaps the former pathological classi-
fication of RCC based on morphological criteria. The
most prominent common genetic aberration for clear-cell
(conventional) RCC is loss of 3p. Characteristic for papil-
lary RCC is trisomy of chromosomes 3q, 7,8,12,16,17,20,
and loss of the Y chromosome, and chromophobe RCC is
characterized by a combination of loss of heterozygosity
at chromosomes 1,2,6,10,13,17, and 21 [1].
Von Hippel-Lindau disease (VHL) is a rare inherited dis-
order associated with, amongst others, an enhanced risk
for clear-cell RCC [2]. The VHL gene responsible for this
syndrome was identified through linkage analyses and
molecular cloning and is located on chromosome 3p25.
After its identification it became evident that the VHL
gene is also involved in the development of sporadic
clear-cell RCC. Together with loss of the homologous
chromosome 3p allele (3p LOH), VHL mutations are rate-
limiting events in the carcinogenesis of clear-cell RCC
[3,4]. Mutations have been observed in the entire gene
and usually lead to a truncated inactive protein [5]. The
VHL gene is considered a tumor suppressor gene, involved
in cell cycle regulation, regulation of hypoxia inducible
genes and proper fibronectin assembly in extracellular
matrix [6,7]. It was estimated that approximately 75% of
all sporadic clear-cell RCC harbor biallelic VHL defects
[8]. In approximately 19% of sporadic clear-cell RCC,
methylation of the VHL gene promoter appeared to be
involved [9]. In approximately 10%–20% of sporadic
clear-cell RCC no alteration in the VHL alleles was
detected, indicating that other genes are involved in clear-
cell RCC carcinogenesis, possibly affecting the same sign-
aling pathway as VHL.
Several risk factors for developing RCC have been identi-
fied: tobacco smoking, obesity, drugs, such as phenacetin,
hypertension and/or its medication, and occupational
exposure to trichloroethylene, gasoline, petroleum prod-
ucts, asbestos, and iron processing fumes. The influence of
dietary factors, such as vegetable, fruit vitamin C, caroten-
oid, meat and milk product consumption, is controversial
[10]. Multiple and specific types of VHL mutations in RCC
have been associated with exposure to the industrial sol-
vent trichloroethylene [11,12]. Consumption of vegeta-
bles and citrus fruit decreased the frequency of VHL
mutations among smokers and consumption of citrus
fruit decreased VHL mutation frequency for all patients
[13]. These findings and investigations in animals [14]
suggest that mutational patterns in the VHL gene may
serve as an etiological imprint to factors causing renal can-
cer. Thus, it may be possible to improve our etiological
insight in particular risk factors when a more specific end-
point than "RCC" can be defined, e.g. based on histology
and mutational status of a gene involved in tumor
carcinogenesis.
We decided to determine the mutational status of the VHL
gene of RCC cases identified within a population-based
cohort of 120,852 men and women aged 55–69 which
was recruited in the Netherlands to study associations
between dietary habits, lifestyle and cancer occurrence. To
validate whether SSCP could serve as a prescreening
method, SSCP and direct sequencing was evaluated in a
subset of 20 patients. In this article we report on his-
topathological and clinical parameters and the type and
number of mutations in VHL observed in a large popula-
tion-based sample of cases.
Methods
Study population
The RCC cases selected for this study were incident cases
identified in the population of the Netherlands Cohort
Study (NLCS) on diet and cancer. The NLCS has been
described in detail elsewhere [15]. Briefly, this prospective
study was initiated in 1986 and included 58,279 men and
62,573 women, 55 to 69 years of age, who completed a
self-administered questionnaire on diet, family history of
cancer, and other risk factors for cancer at baseline. The
entire cohort is being monitored for cancer occurrence by
annual record linkage to the Netherlands Cancer Registry
and to PALGA, a nationwide network and registry of
histo- and cytopathology [16]. Information on sex and
family history of RCC (at baseline) was retrieved from the
NLCS database, while information on age at diagnosis
and tumor localization was retrieved from the Nether-
lands Cancer Registry. Tumor stage was classified accord-
ing to the 1987 revision of the UICC-TNM classification
[17], using information from the cancer registry and the
pathology report. Tumor size was retrieved from the
pathology report.
Tissue sample collection
Paraffin material was collected after approval by the Med-
ical Ethical Committees of Maastricht University, PALGA
and the Netherlands cancer registry. From 1986 to 1997
(11.3 years follow up) 355 kidney cancer cases (ICD-O-3:
C64.9) were identified. Urothelial cell carcinomas were
excluded and only histologically confirmed epithelial
cancers were included (ICD-O: M8010-8119, 8140–
8570), leaving 337 cases. The PALGA database was also
used to identify the location of tumor tissue storage in thePage 2 of 11
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record with information on the location of paraffin mate-
rial was available at the start of the collection of paraffin
blocks. The tissue samples were distributed over 51
pathology laboratories throughout the Netherlands.
For 251/273 cases (92%) paraffin blocks were collected.
Failure to retrieve material was the result of the refusal of
the pathology laboratory to cooperate (3 laboratories with
material for 10 cases), the unavailability of suitable mate-
rial (i.e. only material from a biopsy, cytology or a metas-
tasis was present) (8 cases), not being able to locate the
paraffin block at the laboratory (3 cases), and for 1 case
the reason was not recorded. Paraffin blocks of parallel
normal tissue were collected if available. Collected archi-
val tissue sample blocks were registered and coded using
a unique identification number.
Revision
Genomic DNA was extracted from five 20-µm slices from
each tumor and normal specimen. A flanking section was
haematoxylin and eosin (HE) stained for histological pur-
poses, e.g. grading and estimation of percentage of tumor
cells. One experienced pathologist (CAHK) reviewed all
HE stained slides. The RCC were classified according to
the World Health Organization (WHO) classification of
Tumours of 2002 [18]. Nuclear grading was performed
according to Fuhrman [19]. Grading was based on the
most atypical focus in the paraffin block used for DNA
extraction, with a dimension of at least one high power
field.
Material of 16 cases was discarded after revision. The col-
lected material was unsuitable for analysis, because it con-
cerned a biopsy (N = 2) or a metastasis (N = 2) or no
tumor tissue was present (N = 4) or material contained
less than 10% malignant cells (N = 7) (tumor samples had
to contain at least 10% malignant cells to decrease the
possibility of ignoring mutations). Material from one case
was reclassified as urothelial cell carcinoma and subse-
quently excluded. As a result, tumor DNA from 235 cases
was available for further analysis.
DNA isolation
Genomic DNA was prepared as follows: paraffin was
removed with xylene and genomic DNA was extracted by
salt-precipitation. Briefly, 450 µl of cell lysis solution (10
mM Tris/HCl (pH 7.4), 400 mM NaCl, 2 mM EDTA), 25
µl of 10% SDS and 50 µl of proteinase K solution (20 mg/
ml) were added to the tissue samples and incubated over-
night at 55°C. Proteins were precipitated using 175 µl of
saturated NaCl, followed by centrifugation (2 minutes,
13.200 rpm). DNA was precipitated by the addition of 0.6
volumes of iso-propanol, dissolved in TE (pH 7.4) and
stored at -20°C. The DNA concentration and purity was
measured at 260 and 280 nm.
VHL mutation analysis
PCR primers used for amplification are described in Table
1. Amplification of DNA for SSCP analysis and sequence
analysis was performed as follows: 100 ng of the extracted
DNA was subjected to 35 cycles of PCR: 40 sec at 92°C, 40
sec at Tm and 40 sec at 72°C. Exon amplification was per-
formed in 30 µl of buffer: 50 mM KCl, 10 mM Tris-HCl
(pH 9.0), 1.5 mM MgCl2, 1% triton X-100, 0.1% (w/v)
gelatin, 250 uM dNTP's, 25 pmol of each primer and 1U
Taq polymerase (HT Biotechnology Ltd.). For SSCP anal-
ysis, 0.2 µl of [α 32P] dATP (10 mCi/ml, ~3000 Ci/mmol,
Table 1: Primers used to amplify the VHL gene
Name Sequence 5'>3' Exon Tm Fragment length
Sense3a GGT CTG GAT CGC GGA GGG A 1 64°C * 191 bp
Asense4a GCC CGG CCT CCA TCT CCT 1
Sense5a AGT CGG GCG CCG AGG AGT 1 64°C * 184 bp
Asense6a CCG TCG AAG TTG AGC CAT AC 1
Sense7a CCC AGG TCA TCT TCT GCA AT 1 64°C † 159 bp
Asense8a CTG CTG GGT CGG GCC TAA G 1
Sense9 GTG GCT CTT TAA CAA CCT TTG C 2 60°C‡ 194 bp
Asense10 CCT GTA CTT ACC ACA ACA ACC TTA TC 2
Sense11a CAC TGA GGA TTT GGT TTT TGC 3 55°C 162 bp
Asense12a TCC AGG TCT TTC TGC ACA TTT 3
Sense13a GAC ATC GTC AGG TCG CTC TA 3 55°C 150 bp
Asense14a TCA AAA GCT GAG ATG AAA CAG TG 3
* 3% DMSO added for PCR
† 1.5% DMSO and 2.5 mM MgCl2 added for PCR
‡ 4% DMSO and 1.0 mM MgCl2 added for PCRPage 3 of 11
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For SSCP analyses, 5 µl of the radiolabeled PCR product
was diluted in 5 µl loading buffer (96% formamide, 20
mM EDTA, 0.05% bromophenol blue and xylene cyanol),
boiled for 3 min, and quenched on ice before loading.
Three µl of each sample was loaded on a 0.5x MDE gel,
containing 0.6x TBE either with or without 10% (v/v)
glycerol. Electrophoresis was performed at room temper-
ature at 5W for MDE gels without glycerol, and at 7W for
MDE gels with 10% (v/v) glycerol, using 0.6x TBE as elec-
trophoresis buffer. After 20 hours of electrophoresis, the
gels were transferred to Whatmann 3 MM paper (FIRMA)
and dried on a gel dryer. The separated fragments were vis-
ualized by Hyperfilm-MP (FIRMA) exposure.
For sequence analysis, the PCR products were purified
using the Wizard™ PCR preps purification system
(Promega Corp.). Sequencing was performed at the local
central sequence facility using BigDye Terminator and the
ABI basecaller (Applied Biosystems). Mutations were
identified by visual inspection of sequences provided by
the ABI basecaller, and called when unequivocally present
on the sense and/or antisense strand, and when the area
under the curve of peaks changed by more than 5%, com-
pared to the area under the curve of the normal signal.
Feasibility and comparability pilot
Twenty samples were analyzed by PCR-SSCP and direct
sequencing to investigate the suitability of PCR-SSCP as a
screening tool preceding direct sequencing. After evalua-
tion, we decided to use PCR-SSCP as a screening instru-
ment before direct sequencing. All remaining samples
were subjected to PCR-SSCP, which was only followed by
direct sequencing in case of an aberrant band pattern on
the PCR-SSCP. Samples were also sequenced when equiv-
ocal PCR-SSCP results were obtained.
Statistical analyses
The overall frequency of VHL mutations as well as the type
of mutation and affected exon and codon were computed
for all 235 cases. Differences between histological sub-
types were assessed by the χ2-test. For clear-cell RCC,
mutated and wildtype tumors were compared with respect
to age at diagnosis, sex, grade, TNM classification [17],
stage and family history of RCC. Differences in mean val-
ues of age at diagnosis as a continuous variable were eval-
uated by the student's t-test. Differences in the categorical
variables sex, family history of RCC, grade, TNM classifi-
cation and stage were evaluated for significance by the χ2-
test. A p-value of 0.05 or less was considered statistically
significant. Statistical analyses were performed with the
STATA statistical software package (STATA statistical soft-
ware, Release 7, STATA corporation, College Station, TX,
USA, 2001).
Results
PCR-SSCP as a screening tool preceding direct sequencing
To evaluate whether PCR-SSCP could be used to distin-
guish between wildtype and mutated VHL, we determined
the VHL status of 20 cases by SSCP and direct sequencing
(Table 2). SSCP and direct sequencing were mostly in
agreement. In all cases where disparate results were
obtained, this concerned aberrant signals in PCR-SSCP,
followed by a negative result by direct sequencing (Table
2). Most importantly, we never found a mutation in the
sequence analysis after a negative PCR-SSCP (0% false-
negatives) (Table 2). However, we are aware that the
sampling size is limited, and it is known that SSCP as a
screening tool is neither 100% sensitive nor specific.
Therefore, we estimated the chance of a positive result on
direct sequencing after a negative result on the SSCP (i.e.,
the chance that a mutation will be missed by using SSCP
as a screening instrument). The point estimate for the per-
centage of false-negatives based on SSCP is 0%, with an
upper confidence limit between 3.7% and 16.9%, based
either on the individual analyses (N = 97), or on the
number of cases (N = 20) (see Additional file 1: Calcula-
tion of the estimated upper 95% confidence limit). Differ-
ent types of mutations were identified by SSCP followed
by direct sequencing in this pilot.
Table 2: Mutation analysis in 20 samples by SSCP and direct 
sequencing
Direct sequencing
Positive Negative
Primerset 3/4
SSCP Positive 0 5
Negative 0 15
Primerset 5/6
SSCP Positive 2 0
Negative 0 18
Primerset 7/8
SSCP Positive 4 2
Negative 0 14
Primerset 9/10
SSCP Positive 3 0
Negative 0 17
Primerset 11/12
SSCP Positive 4 1
Negative 0 15
Primerset 13/14
SSCP Positive 2 0
Negative 0 18
Positive on SSCP means: indication of a mutation or not assessable 
after two attempts.
Positive on direct sequencing means: proof of a mutation.Page 4 of 11
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We were able to analyze at least one tumor block for 235
patients with 236 tumors (one patient had two primary
tumors). After revision by CAHK, the analyzed samples
could be subdivided as follows: clear-cell RCC (188/236,
79.7%), papillary RCC (30/236, 12.7%); chromophobe
RCC (7/236, 3.0%); oncocytoma (6/236, 2.5%), collect-
ing duct carcinoma (1/236, 0.4%), and unclassified RCC
(4/236, 1.7%). For 198 cases one paraffin block was ana-
lyzed, while for 34 cases 2 paraffin blocks were analyzed
and for 3 cases 3 paraffin blocks were analyzed. In 10
cases, a different genotype was observed in different
tumor blocks obtained from 1 tumor. In 6 cases, 1 sample
contained wildtype VHL while the other sample harbored
one or more mutations. For the statistical analyses these
cases were analyzed as "mutated". In 13 cases, 2 muta-
tions in the same paraffin block were observed. In one
patient with two primary tumors, both tumors showed a
different mutation. In total we observed 253 outcomes
(139 mutations (in 121 patients) and 114 wildtype) for
235 patients with 236 primary tumors. All 139 observed
mutations are described. (see Additional file 2: Descrip-
tion of observed mutations (N = 139), histological param-
eters and personal characteristics for 121 cases).
VHL gene mutations were mostly observed in clear-cell
RCC, but also in unclassified RCC (2/4); papillary RCC
(2/30); chromophobe RCC (3 mutations in 2/7 patients)
and oncocytoma (1/6) (see Additional file 2: Description
of observed mutations (N = 139), histological parameters
and personal characteristics for 121 cases). The percentage
of patients with a mutation was significantly higher for
clear-cell tumors compared to tumors of other histologi-
cal types (χ2: 32.9; p-value<0.001). In the remainder of
this paper, we will only consider clear-cell RCC, leaving
204 outcomes (131 mutations (in 114 patients) and 73
wildtype) for 187 patients with 188 primary tumors. Nine
outcomes were mutations in intronic sequences, possibly
affecting splicing. The majority of observed mutations in
coding regions lead to a truncated VHL product
(insertion/deletion mutations leading to a frameshift and
nonsense mutations, 62/122) or to a deleted/inserted or
altered amino acid, 47/122). The percentage of point
mutations was much higher in exon 1 (50.7%) than in
exon 2 and 3 (29.6 and 23.1, respectively).
Figure 1 shows the type of mutation plotted against the
codon number. We observed 62 truncating mutations,
which consisted of 4 nonsense mutations and 58 dele-
tions or insertions leading to a shift of the reading frame
(Figure 1A), 15 insertions or deletions that did not affect
the reading frame (Figure 1B), 32 missense mutations
(Figure 1C) and 13 silent mutations (Figure 1D).
Cases with a mutation were older (mean: 67.8 years; sd:
4.7) than cases without a mutation (mean: 67.1; sd: 4.6).
The mean age difference at diagnosis was 0.8 years with a
95% CI ranging from -0.6 through 2.2 years. The percent-
age of men with clear-cell RCC with a VHL mutation was
somewhat higher than the percentage of males among
patients with a clear-cell RCC without a VHL mutation,
63.2 % vs. 53.4% (χ2: 1.75; p-value: 0.19).
The mean tumor size was 72.7 mm for tumors with a VHL
mutation compared to 65.3 mm for tumors without a
VHL mutation. The difference was 7.3 mm with a 95% CI
from -2.1 mm through 16.8 mm. Other tumor parameters
for patients with a primary clear-cell RCC with or without
a VHL mutation are shown in Table 3. We did not observe
a difference in nuclear grade, T, N, M, or stage between
mutated and wildtype tumors.
For 3 patients, a positive family history was reported; 2 of
these patients (Sample id's: 1003 and 306/1600) had a
clear-cell tumor harboring a mutation. One patient with a
papillary tumor reported a positive family history; no
mutations in the VHL gene were observed in the corre-
sponding tumor sample. Obviously, these numbers are
too small to engage in statistical testing.
Discussion
The von Hippel-Lindau (VHL) gene is a tumor suppressor
gene predisposing to both sporadic clear-cell (conven-
tional) RCC and von Hippel-Lindau disease. We analyzed
235 cases of primary sporadic RCC, of which 187 cases
presented with the histological subtype clear-cell RCC,
identified within the Netherlands cohort study on diet
and cancer. VHL mutations were assessed by PCR-SSCP,
followed by direct sequencing when aberrant signals were
detected in SSCP. Screening by SSCP was considered
appropriate, since we never detected a mutation by direct
sequencing after a negative result on the SSCP in a pilot
study. Furthermore, we estimated the upper 95% confi-
dence limit for cases missed at 3.7% or 16.9%, based on
the individual analyses (N = 97) or on the number of cases
(N = 20). Therefore, mutated cases may have been over-
looked, which placed them in the wildtype group. This
would have resulted in a reduction of contrast between
wildtype and mutated groups.
We observed 131 mutations in 114 out of 187 patients
(61%) in patients with clear-cell tumors. Estimates
reported in the literature [2,20-30] range from 36% [25]
to 54% [27], and therefore our estimate appears high.
However, our estimate is close to the estimate of 75% as
discussed in the review by Cohen [8]. This difference in
the observed proportion of mutations in the VHL gene
may be attributed to the use of different techniques, e.g.,
SSCP vs. direct sequencing, to contamination with normalPage 5 of 11
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Type of mutation plotted against the codon number. A. Truncating mutations (Frameshift & Nonsense mutations) B. 
In-frame insertions/deletions C. Missense mutations D. Silent mutations Codon 1–114 encodes exon 1, codon 114–155 
encode exon 2, and codon 155–213 encode exon 3.
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(fresh or archival paraffin material). In our study, we used
SSCP followed by direct sequencing, as most investiga-
tions did [2,20-29]. To avoid ignoring VHL mutations
through contamination with normal tissue, samples
needed to contain at least 10% tumor cells. The vast
majority of samples (180 out of 190) contained at least
50% viable tumor tissue. The sample with the lowest per-
centage of viable tumor tissue, in which we observed a
mutation, contained 30% of viable tumor tissue. For 2
samples the percentage of viable tumor tissue was lower
(10% and 20%), thus we cannot formally exclude the pos-
sibility that we overlooked an existing mutation. We iden-
tified cases in a population-based study after 11.3 years of
follow-up; the time span and the number of patients and
hospitals involved excluded the possibility to collect fresh
material. Three other studies on sporadic RCC used paraf-
fin embedded material and the percentages of mutations
detected were 46% [29], 50% [22] and 54% [27].
The occurrence of various types of mutations is compara-
ble to other studies of this size [21,24,26,27], but some
differences are also apparent. The presence of silent muta-
tions is not commonly reported; only Ma et al. [27]
reported 13% of silent mutations, similar to 11%
observed by us. It is possible that others do not report
silent mutations because the investigators do not wish to
designate these as true mutations since their relevance is
unclear. The percentage of frameshift mutations was
approximately 50% in most studies [21,26], comparable
to the 48% observed in the current study. The percentage
of in-frame deletions/insertions was higher in our study
Table 3: Tumor parameters for patients with a clear-cell tumor, also stratified by VHL mutation status
All tumors (N = 188) VHL mutated tumors (N = 115) Wildtype tumors (N = 73)
N % N % N % χ2 p-value †
T (TNM*)
1 5 2.7 4 3.5 1 1.4
2 93 49.5 55 47.8 38 52.1
3A 35 18.6 20 17.4 15 20.6
3B 50 26.6 34 29.6 16 21.9
4 2 1.1 1 0.9 1 1.4 0.18§** 0.67
X 3 1.6 1 0.9 2 2.7
N (TNM*)
0 126 67.0 78 67.8 48 65.8
1 7 3.7 6 5.2 1 1.4
2 7 3.7 5 4.4 2 2.7 1.51¶** 0.22
X 48 25.5 26 22.6 22 30.1
M (TNM*)
0 131 69.7 77 67.0 54 74.0
1 26 13.8 18 15.7 8 11.0 0.99** 0.32
X 31 16.5 20 17.4 11 15.1
Stage (TNM*)
1 5 2.7 4 3.5 1 1.4
2 83 44.2 46 40.0 37 50.7
3 66 35.1 42 36.5 24 32.9
4 32 17.0 22 19.1 10 13.7 1.41§** 0.24
X 2 1.1 1 0.9 1 1.4
Nuclear grading †‡
I 46 24.5 27 23.5 19 26.0
II 67 35.6 43 37.4 24 32.9
III 48 25.5 29 25.2 19 26.0
IV 27 14.4 16 13.9 11 15.1 0.43 0.94
* Based on pathological TNM unless unknown, then clinical TNM (UICC, 1987) was used [17]
† Based on the review by one experienced pathologist (CAHK)
‡ According to Fuhrman [19]
§1–2 vs. 3–4
¶1–2 vs. 0
** Excludes "X (unknown) " categoryPage 7 of 11
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(<5%) [21,26]. Compared to the distribution of mutation
data present in the Universal VHL Mutation database with
747 mutations [31], the relative amount of point muta-
tions is much higher in the database (64%), compared to
the percentage of point mutations we observed (44%), as
well as the frequency of nonsense mutations (11% vs.
3%). However, many of the mutations in the Mutation
database concern germline mutations identified in VHL-
families. It has been suggested that the mutational spec-
trum between germline and sporadic VHL mutations may
differ [25], which could explain the disparity. We were not
able to select records for sporadic tumors in the database,
but Gallou et al. [26] described mutations for 145 spo-
radic cases from this database. Compared to our results,
the percentage of nonsense mutations was higher (8% vs.
3%) and the percentage of in-frame deletions or inser-
tions was lower (4% vs. 12%) [26].
Furthermore, we searched the Universal VHL Mutation
database [31] for the mutations observed in the cases with
a positive family history of RCC. The T>A (silent) muta-
tion at codon 139 (sample id 1003) was not reported
before, the deletion of 1 nucleotide at codon 146 (sample
id 306) was recorded in the database twice, while the sec-
ond 1 nucleotide deletion at codon 167 (sample id 1600)
had not been reported before.
For 10 RCC cases, we observed different VHL genotypes in
different tumor samples obtained from one tumor. Sam-
ples were re-analyzed to exclude technical errors. Again,
different VHL genotypes, identical to the earlier geno-
types, were observed, showing that tumor heterogeneity
appears to play a role. This was an unexpected finding in
view of the general acceptance that a mutation in the VHL
gene is an early event in clear-cell RCC carcinogenesis,
because one would then expect monogenetic VHL expres-
sion. Nevertheless, it is possible that genetic instability
leads to additional mutational events, eventually leading
to different VHL genotypes in clear-cell RCC. This was
underscored by 13 cases showing 2 mutations within the
same paraffin block and other studies have also reported
multiple mutations per primary tumor [21,27,29].
The distribution of histological subtypes was comparable
to the distribution described before [[32], p2692]. Sur-
prisingly, we also found VHL mutations in some of the
non-clear-cell RCC samples that were collected. These
results are in contrast with the current opinion that VHL
mutations are exclusively restricted to clear-cell RCC. VHL
mutations, however, have also been reported in chromo-
phobe RCC, although these were clustered in the 5'UTR/
promoter region [22], and Brauch et al. [12] described a
renal oncocytoma with a VHL mutation. To our knowl-
edge, others have not yet described VHL mutations in pap-
illary RCC. It is conceivable that genetic instability
following tumor-initiating events leads to VHL mutations
acquired at a later stage of tumor development. As
expected, the relative occurrence of VHL mutations in the
non-clear-cell RCC renal tumors was much lower than in
clear-cell RCC, emphasizing the crucial role of VHL muta-
tions in clear-cell RCC carcinogenesis.
The high percentage of mutations observed, the observa-
tion of mutational heterogeneity (different genotypes in 1
or different samples from the same tumor), and the obser-
vation of mutations in other histological types, raises the
question whether paraffin material is suitable for analysis.
It has been shown, however, that VHL gene mutations can
be detected in archival paraffin material [33]. Identical
mutations were observed in exon 2 in 3 cases for which
archival paraffin material and tumor derived cell lines
were assessed by SSCP and sequencing [33]. On the other
hand, it has also been reported that artifacts may occur
when archival paraffin material is used [34]. Williams et
al. reported up to 1 mutation artifact per 500 bases
recorded. The chance of such artificial mutations in for-
malin-fixed material was inversely correlated with the
number of cells used in the PCR: the fewer the cells, the
more artifacts. No artifacts were observed when 300 cells
were used and only 1 artifact was observed in 150 cells
(0.03%). The highest frequency of artifacts was observed
when using 10 or 20 cells, and equaled 0.2 % [34]. The
number of cells in our analyses, however, was large (>500
cells), since 5 20-µm slices of paraffin embedded material
were used and biopsies were excluded.
The mean tumor size was larger for mutated tumors than
for wildtype tumors, however not statistically significant.
Two other studies did not show a difference in tumor size
[24,28]. VHL gene mutations leading to reduced or inac-
tive VHL protein (pVHL) could theoretically lead to a
larger tumor size. In the absence of pVHL, hypoxia induc-
ible factor becomes stabilized and upregulates a myriad of
hypoxia-inducible genes, resulting in hypervascular
tumors [35]. This should be a growth advantage. Our
results and results from others [24,28] showed no associ-
ation with nuclear grade (according to Fuhrman) [19]. It
was difficult to compare TNM and stage, since different
classifications were used in different studies and the TNM
classification has changed definitions in recent years. We
reviewed all cases and classified them according to the
1987 version of the TNM classification [17]. We did not
observe a difference in T, N, M, or stage between mutated
and wildtype tumors, as was confirmed by 2 other studies
[24,28]. One study, however, reported a higher percentage
of mutations in pT3 tumors with a VHL mutation or
hypermethylation, compared to tumors without VHL
alteration (64% vs. 40%) [21].Page 8 of 11
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impair pVHL function. However, in order for pVHL to
lose its function, biallelic VHL defects have to occur. We
did not measure LOH, since it is well documented that
LOH commonly occurs in RCC cases, with estimates rang-
ing from 74% [30] to 93% [21]. Kondo et al. showed 97%
LOH in mutated or hypermethylated samples compared
to 81% LOH in wildtype samples [24]. Furthermore,
silent mutations do not lead to an altered protein, but
these types of mutations were not common (13/131) in
our study. Also, pVHL formation may be inhibited by epi-
genetic silencing, which has been reported to occur in
19% of clear-cell RCC [9]. This could have resulted in mis-
classification in comparing pathological parameters,
because samples with epigenetic silencing only were clas-
sified as wildtype tumors, as we were not able to investi-
gate epigenetic silencing in the current study. Finally, cells
in cell culture have been shown to produce two types of
proteins: pVHL30 and pVHL19 (a results of internal trans-
lation from the second methionine within the VHL open
reading frame (Met 54) [36-38]. The pVHL19 product has
been shown to inhibit the production of hypoxia-induci-
ble genes, but does not bind to fibronectin [36,37].
Reintroduction of pVHL19 has been shown to inhibit
tumor formation in nude mice [37]. We detected muta-
tions 5' of codon 54 in 11 cases; these are unusual and
would be predicted to affect pVHL30, but not pVHL19
translation products. However in 5 of these 11 cases, a
second mutation was observed 3'of codon 54. So, in 5 of
these cases the other mutation may be relevant. For the
other 6 cases, these mutations may not lead to a function-
ally inactive protein, and thus we may have misclassified
these. However, as remarked before, the pVHL19 variant
does not bind to fibronectin and thus may not contribute
to the maintenance of the extracellular matrix.
Conclusion
VHL mutations were observed in 61% of sporadic clear-
cell RCC. No differences were observed in nuclear grade,
TNM distribution or stage between VHL mutated and
wildtype clear-cell RCC. However, the tumor size was
larger for VHL mutated clear-cell RCC. This study forms a
good basis to study possible associations between poten-
tial risk factors and VHL mutations in clear-cell RCC. Ulti-
mately, this should lead to greater insight in the etiology
of clear-cell RCC.
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